Pharmacokinetics of midazolam in neonates undergoing extracorporeal membrane oxygenation

Anesthesiology

Volumn 99, Issue 2, 2003, Pages 275-282

  Mulla, Hussain ^a   McCormack, Peter ^b   Lawson, Graham ^b   Firmin, Richard K ^b   Upton, David Robert ^b  

^a GLENFIELD HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

1 HYDROXYMIDAZOLAM; DRUG METABOLITE; MIDAZOLAM; UNCLASSIFIED DRUG;

ARTICLE; BLOOD SAMPLING; CENTRAL VENOUS CATHETER; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL ILLNESS; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG OVERDOSE; EXTRACORPOREAL OXYGENATION; FEMALE; HUMAN; MALE; MATHEMATICAL ANALYSIS; NEWBORN; NEWBORN SURGERY; OVERSEDATION; PEDIATRIC ANESTHESIA; PERIPHERAL VEIN; PLASMA HALF LIFE; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEDATION; SIDE EFFECT; SIMULATION; STATISTICAL SIGNIFICANCE; STEADY STATE; TIME; VASCULAR ACCESS; VOLUMETRY;

EID: 0042344946     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-200308000-00008     Document Type: Article

References (39)

1. Mulla H, Lawson G, Woodland E, Peek G, Killer H, Firmin R, Upton D: Neonatal ECMO affects drug disposition. Curr Ther Res: Clin Exp 2000; 61:838-48
2. Jacqz-Aigrain E, Daoud P, Burtin P, Maherzi S, Beaufils F: Pharmacokinetics of midazolam during continuous infusion in critically ill neonates. Eur J Clin Pharmacol 1992; 42:329-32
3. de Wildt S, Kearns G, Hop W, Murry D, Abdel-Rahman S, van den Anker J: Pharmacokinetics and metabolism of intravenous midazolam in preterm infants. Clin Pharmacol Ther 2001; 70:525-31
4. Jacqz-Aigrain E, Wood C, Robieux I: Pharmacokinetics of midazolam in critically ill neonates. Eur J Clin Pharmacol 1990; 39:191-92
5. Burtin P, Jacqz-Aigrain E, Girard P, Lenclen R, Magny J, Betremieux P, Tehiry C, Desplanques L, Mussat P: Population pharmacokinetics of midazolam in neonates. Clin Pharmacol Ther 1994; 56:615-25
6. Lee T, Charles B, Harte G, Gray P, Steer P, Flenady V: Population pharmacokinetic modeling in very premature infants receiving midazolam during mechanical ventilation: Midazolam neonatal pharmacokinetics. ANESTHESIOLOGY 1999; 90:451-57
7. Mulla H, Lawson G, Firmin R, Upton D: Drug disposition during extracorporeal membrane oxygenation (ECMO). Paediatr Perinat Drug Ther 2001; 4:109-20
8. Dagan O, Klein J, Gruenwald C, Bohn D, Barker G, Koren G: Preliminary studies of the effects of extracorporeal membrane oxygenator on the disposition of common paediatric drugs. Ther Drug Monit 1993; 15:263-66
9. Mulla H, Lawson G, von Anrep C, Burke M, Upton D, Firmin R, Killer H: In vitro evaluation of sedative drug losses during extracorporeal membrane oxygenation. Perfusion 2000; 15:21-26
10. Mulla H, Lawson G, von Anrep C, Burke M, Upton D, Firmin R, Killer H: Plasma concentrations of midazolam in neonates receiving extracorporeal membrane oxygenation. ASAIO J 2003; 49:41-47
11. Sheiner L, Rosenberg B, Arathe V: Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm 1977; 5:445-79
12. Sun H, Fadiran E, Jones C, Lesko L, Huang S-M, Higgins K, Hu C, Machado S, Maldonado S, Williams R, Hossain M, Ette E: Population Pharmacokinetics: A regulatory perspective. Clin Pharmacokinet 1999; 37:41-58
13. Fiset P, Mathers L, Engstrom R, Fitzgerald D, Brand S, Hsu F, Shafer S: Pharmacokinetics of computer-controlled alfentanil administration in children undergoing cardiac surgery. ANESTHESIOLOGY 1995; 83:944-55
14. Zomorodi K, Donner A, Somma J, Barr J, Sladen R, Ramsay J, Geller E, Shafer S: Population pharmacokinetics of midazolam administered by target controlled infusion for sedation following coronary artery bypass grafting. ANESTHESIOLOGY 1998; 89:1418-29
15. Kerbusch T, Kraker JD, Mathot R, Beijnen J: Population pharmacokinetics of ifosfamide and its dechloroethylated and hydroxylated metabolites in children with malignant disease: A sparse sampling approach. Clin Pharmacokinet 2001; 40:615-25
16. Sheiner L, Beal S: Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981; 9:503-12
17. Johnson T, Rostami-Hodjegan A, Goddard J, Tanner M, Tucker G: Contribution of midazolam and its 1-hydroxy metabolite to preoperative sedation in children: A pharmacokinetic-pharmacodynamic analysis. Br J Anaesth 2002; 89:428-37
18. Rostami-Hodjegan A, Wolff K, Hay A, Raistrick D, Calvert R, Tucker G: Population pharmacokinetics of methadone in opiate users: Characterisation of time-dependent changes. Br J Clin Pharmacol 1999; 48:43-52
19. Wills R, Khoo J, Soni P, Patel I: Increased volume of distribution prolongs midazolam half-life. Br J Clin Pharmacol 1990; 29:269-72
20. Matthews H, Carson I, Lyons S, Orr I, Collier P, Howard P, Dundee J: A pharmacokinetic study of midazolam in paediatric patients undergoing cardiac surgery. Br J Anaesth 1988; 61:302-7
21. Payne K, Mattheyse F, Liebenberg D, Dawes T: The pharmacokinetics of midazolam in paediatric patients. Eur J Clin Pharmacol 1989; 37:267-72
22. Hughes J, Gill A, Mulhearn H, Powell E, Choonara I: Steady-state plasma concentrations of midazolam in critically ill infants and children. Ann Pharmacother 1996; 30:27-30
23. Arnold J, Truog R, Orav E, Scavone J, Hershenson M: Tolerance and dependence in neonates sedated with fentanyl during extracorporeal membrane oxygenation. Anaesthesiology 1990; 73:1136-40
24. Arnold J, Truog R, Orav E, Scavone J, Fenton T: Changes in the pharmacodynamic response to fentanyl in neonates during continuous infusion. J Pediatr 1991; 119:639-43
25. Leushen M, Willett L, Hoie E, Bolam D, Bussey M, Goodrich P, Zach T, Nelson R: Plasma fentanyl levels in infants undergoing extracorporeal membrane oxygenation. J Thorac Cardiovasc Surg 1993; 105:885-91
26. Ngiam S, Chong J: The addition of intrathecal sufentanil and fentanyl to bupivacaine for caesarean section. Singapore Med J 1998; 39:290-94
27. Koren G, Crean P, Klein J, Goresky G, Villamater J, MacLeod S: Sequestration of fentanyl by the cardiopulmonary bypass (CPBP). Eur J Clin Pharmacol 1984; 27:51-56
28. Skacel M, Knott C, Reynolds F, Aps C: Extracorporeal circuit sequestration of fentanyl and alfentanil. Br J Anaesth 1986; 58:947-49
29. Hynynen M: Binding of fentanyl and alfentanil to the extracorporeal circuit. Acta Anaesthesia Scandinavica 1987; 31:706-10
30. Rosen D, Rosen K, Davidson B, Broadman L: Fentanyl uptake by the Scimed Membrane Oxygenator. J Cardiothorac Anesth 1988; 2:619-26
31. Rosen D, Rosen K, Silvasi D: In vitro variability in fentanyl absorption by the different membrane oxygenators. J Cardiothorac Anesth 1990; 4:332-35
32. Hartwig S, Roth B, Theisohn M: Clinical experience with continuous intravenous sedation using midazolam and fentanyl in the paediatric intensive care unit. Eur J Pediatr 1991; 150:784-88
33. Reves J, Fragen R, Vinik H, Greenblatt D: Midazolam: Pharmacology and uses. ANESTHESIOLOGY 1987; 62:310-24
34. de Wildt S, Kearns G, Leeder J, van den Anker J: Cytochrome P450 3A: Ontogeny and drug disposition. Clin Pharmacokinet 1999; 37:485-505
35. Thummel K, Shen D, Podoll T, Kunze K, Trager W, Hartwell P, Raisys V, Marsh C, McVicar J, Barr D: Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 1994; 271:549-56
36. Wrighton S, Brian W, Sari M, Iwasaki M, Guengerich F, Raucy J, Molowa D, Vandenbranden M: Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol 1990; 38:207-13
37. Mandema J, Tuk B, van Steveninck A, Breimer D, Cohen A, Danhof M: Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers. Clin Pharmacol Ther 1992; 51:715-28
38. Lloyd-Thomas A, Booker P: Infusion of midazolam in paediatric patients after cardiac surgery. Br J Anaesth 1986; 58:1109-15
39. Lacroix D, Sonnier M, Monion A, Cheron G, Cresteil T: Expression of CYP3A in the liver: Evidence that the shift beween CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem 1997; 247:625-34